AptaBio Therapeutics Inc. акциялары

AptaBio Therapeutics Inc. specializes in the discovery and advancement of innovative therapeutic agents. Its core activities encompass developing specific inhibitors for the NOX enzyme family and crafting aptamer-based anti-cancer medicines. Additionally, the company supplies a range of transfection reagents, including Lipofector-Q, Lipofector-EXT, Lipofector-2000, Lipofector-EZ, and Lipofector-pMAX Reagent, which are utilized for introducing DNA or RNA into eukaryotic cells. Key drug candidates in its pipeline include PX-115, designed to address diabetic nephropathy; APX-1004, intended for diabetic retinopathy; and APX-311, targeting non-alcoholic steatohepatitis (NASH). Founded in 2009, AptaBio Therapeutics is headquartered in Yongin-Si, South Korea.